232 related articles for article (PubMed ID: 25002250)
1. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.
Truran PP; Johnson SJ; Bliss RD; Lennard TW; Aspinall SR
World J Surg; 2014 Nov; 38(11):2845-54. PubMed ID: 25002250
[TBL] [Abstract][Full Text] [Related]
2. Molecular Characteristics of Large Parathyroid Adenomas.
Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
[TBL] [Abstract][Full Text] [Related]
3. Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms.
Kumari N; Chaudhary N; Pradhan R; Agarwal A; Krishnani N
Endocr Pathol; 2016 Jun; 27(2):87-96. PubMed ID: 26984237
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
[TBL] [Abstract][Full Text] [Related]
5. Role of calcium-sensing receptor, Galectin-3, Cyclin D1, and Ki-67 immunohistochemistry to favor in the diagnosis of parathyroid carcinoma.
Sungu N; Dogan HT; Kiliçarslan A; Kiliç M; Polat S; Tokaç M; Akbaba S; Parlak Ö; Balci S; Ögüt B; Çakir B
Indian J Pathol Microbiol; 2018; 61(1):22-26. PubMed ID: 29567879
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
[TBL] [Abstract][Full Text] [Related]
7. Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms.
Silva-Figueroa AM; Bassett R; Christakis I; Moreno P; Clarke CN; Busaidy NL; Grubbs EG; Lee JE; Perrier ND; Williams MD
Endocr Pathol; 2019 Dec; 30(4):285-296. PubMed ID: 31734935
[TBL] [Abstract][Full Text] [Related]
8. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.
Juhlin CC; Nilsson IL; Lagerstedt-Robinson K; Stenman A; Bränström R; Tham E; Höög A
Mod Pathol; 2019 Jul; 32(8):1082-1094. PubMed ID: 30923346
[TBL] [Abstract][Full Text] [Related]
9. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
[TBL] [Abstract][Full Text] [Related]
10. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
[TBL] [Abstract][Full Text] [Related]
11. Defining a molecular phenotype for benign and malignant parathyroid tumors.
Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
[TBL] [Abstract][Full Text] [Related]
12. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
[TBL] [Abstract][Full Text] [Related]
13. p53, Ki67 and cyclin D1 as prognosticators of lymph node metastases in laryngeal carcinoma.
Mielcarek-Kuchta D; Olofsson J; Golusinski W
Eur Arch Otorhinolaryngol; 2003 Nov; 260(10):549-54. PubMed ID: 14551784
[TBL] [Abstract][Full Text] [Related]
14. Filamin A and parafibromin expression in parathyroid carcinoma.
Storvall S; Leijon H; Ryhänen EM; Vesterinen T; Heiskanen I; Schalin-Jäntti C; Arola J
Eur J Endocrinol; 2021 Oct; 185(6):803-812. PubMed ID: 34606470
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry in Diagnostic Parathyroid Pathology.
Erickson LA; Mete O
Endocr Pathol; 2018 Jun; 29(2):113-129. PubMed ID: 29626276
[TBL] [Abstract][Full Text] [Related]
16. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
[TBL] [Abstract][Full Text] [Related]
17. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic significance of parafibromin expression in parathyroid carcinoma.
Gao Y; Wang P; Lu J; Pan B; Guo D; Zhang Z; Wang A; Zhang M; Sun J; Wang W; Liang Z
Hum Pathol; 2022 Sep; 127():28-38. PubMed ID: 35654240
[TBL] [Abstract][Full Text] [Related]
19. Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma.
Delellis RA
Endocr Pathol; 2008; 19(4):221-5. PubMed ID: 19058032
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases.
Bergero N; De Pompa R; Sacerdote C; Gasparri G; Volante M; Bussolati G; Papotti M
Hum Pathol; 2005 Aug; 36(8):908-14. PubMed ID: 16112008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
